NCT05040698View on ClinicalTrials.gov

Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa

PHASE2CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

January 13, 2023

Study Completion Date

January 27, 2023

Conditions

Hidradenitis Suppurativa

Interventions

DRUG

Fostamatinib

Open label Fostamatinib

Trial Locations (1)

2010

Holdsworth House Medical Practice, Sydney

Sponsors

Collaborators (1)

Rigel Pharmaceuticals

All Listed Sponsors

collaborator

Rigel Pharmaceuticals

INDUSTRY

lead

Holdsworth House Medical Practice

OTHER